Trial intelligence / Profile preview

Phase II open-label single-arm study of HA121-28 in RET fusion-positive advanced non-small cell lung cancer

CTR20212821Phase 2Terminated

Sponsor

CSPC ZhongQi Pharmaceutical Technology

Start

Apr 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1